Pharming Group Welcomes Kenneth Lynard as CFO for Growth
Pharming Group Strengthens Financial Leadership
Pharming Group N.V. has made a significant move in its leadership by appointing Kenneth Lynard as the Chief Financial Officer (CFO). As of October 1, 2025, Mr. Lynard's expertise will be pivotal for the company as it continues its focus on growth and development within the biopharmaceutical industry.
Kenneth Lynard: An Experienced Financial Executive
Mr. Lynard brings with him over 20 years of rich experience in the life sciences sector, demonstrating outstanding skills in financial operations and transformation. His previous roles have included notable positions within complex, multinational organizations which have honed his ability to navigate the intricacies of global finance.
Recent Achievements and Financial Growth
His appointment follows a successful first half of the financial year at Pharming. The company is looking to leverage his extensive background to enhance its financial strategies further. Kenneth's leadership is seen as crucial in Cambia's mission to build a prominent company focused on exceptional patient care facilitated by robust financial management.
Comments from Leadership
The CEO of Pharming, Fabrice Chouraqui, expressed his enthusiasm regarding Lynard's appointment, noting, "We are thrilled to welcome Kenneth at this crucial point in our journey. His extensive finance expertise from both established and emerging companies is what we need as we strive to expand our impact in the rare disease sector. His past experiences will be invaluable as we work to achieve our goals and ensure sustainable growth."
Professional Background of Kenneth Lynard
Before joining Pharming, Kenneth served as the CFO at Schoeller Allibert and Zentiva, demonstrating his ability to manage finance in the pharmaceutical domain effectively. Previous roles have included being CFO at Affidea and a significant tenure at Gilead Sciences, where he was instrumental in capital allocation strategies during times of substantial company growth.
Educational Background
Kenneth holds a Master of Science in Business Economics and Auditing from the Copenhagen Business School and an executive MBA from the IMD in Lausanne, Switzerland. His education combined with his practical experience creates a solid ground for leading Pharming's financial strategies.
About Pharming Group N.V.
Pharming Group N.V. is recognized as a global biopharmaceutical leader actively engaged in developing and commercializing innovative treatments for patients with rare and serious diseases. With a presence in over thirty markets across various regions including North America and Europe, Pharming is dedicated to creating life-changing therapies, including both small molecules and biologics.
The company continuously invests in R&D to ensure the development of effective medications that address significant medical needs. Its headquarters in Leiden serves as a hub for the teams dedicated to pushing the boundaries of what is possible in rare disease treatment.
Contact Information for Pharming
If you are looking for more information about Pharming Group, please feel free to reach out:
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
Saskia Mehring, Corporate Communications Manager
T: +31 6 28 32 60 41
Frequently Asked Questions
Who is the new Chief Financial Officer of Pharming Group?
The new CFO of Pharming Group is Kenneth Lynard, effective October 1, 2025.
What experience does Kenneth Lynard bring to Pharming?
Kenneth Lynard has over 20 years of experience in the life sciences sector, having held senior finance roles in prominent pharmaceutical companies.
What is Pharming Group's focus area?
Pharming Group is dedicated to developing and commercializing treatments for rare and serious diseases.
Where is Pharming Group located?
Pharming Group is headquartered in Leiden, the Netherlands.
How can I get in touch with Pharming Group?
You can contact Pharming Group's Investor Relations via email at investor@pharming.com.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
